N/A N=35 Treatment

The Effects of Sertraline on Depression in Parkinson's Disease

Depression · Parkinson's Disease

Bottom Line

View on ClinicalTrials.gov: NCT01437189 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2024

Primary outcome: Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD) — 48.1; 35.5 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Sertraline (Drug)
Age: Adult, Older Adult · 35+ yrs
Sex: All
Sponsor: Zhejiang University
Primary completion: Aug 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Hamilton Depression Rating Scale (HAMD)	48.1; 35.5	—
SECONDARY Change From Baseline in Questionnaire of PDQ-39,	51; 46	—

Summary

The aim of this open-label, self-control study is to evaluate the efficacy of sertraline in treating depression in Patients with Parkinson's disease. In addition, the investigators also want to find out whether patient gets better quality of life when depression is improved.

Eligibility Criteria

Inclusion Criteria

Patients between 35 and 75 years of age from the outpatients clinic in Department of Neurology, the Second Affiliated Hospital, School of Medicine, Zhejiang University.
All patients should have a confirmed diagnosis of PD according to Brain Bank Criteria.
Diagnosed to be major depression episode according to DSM-IV,
Mini Mental State Examination (MMSE) exclude dementia.

Exclusion Criteria

Mini-Mental State Examination (MMSE) demonstrate dementia
Any current DSM-IV Axis I diagnosis other than a depressive or anxiety disorder.
History of psychosis or hallucinations or under treatment with atypical neuroleptics.
Treatment-resistant depression. Treatment-resistant depression (TRD) occurs when a patient with unipolar depression fails to respond to adequate antidepressant therapy.
Pregnancy or lactation.
Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).
Concomitant use in patients taking pimozide.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01437189). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.